Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy

References

• Drexler M. Institute of M In: What You Need to Know About Infectious Disease. Washington (DC): National Academies Press (US) Copyright © National Academy of Sciences.; 2010.
   Google Scholar
• Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med. 2012;366(5):454–461. doi:10.1056/NEJMra110829622296079
   PubMed Web of Science ®Google Scholar
• Liu Q, Xu W, Lu S, et al. Landscape of emerging and re-emerging infectious diseases in China: impact of ecology, climate, and behavior. Front Med. 2018;12(1):3–22. doi:10.1007/s11684-017-0605-929368266
   PubMed Web of Science ®Google Scholar
• Collaborators G. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016;22(11):946–957.27692880
   PubMed Web of Science ®Google Scholar
• Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885–891.12490963
   PubMed Web of Science ®Google Scholar
• Anjos LM, Marcondes MB, Lima MF, Mondelli AL, Okoshi MP. Streptococcal acute pharyngitis. Rev Soc Bras Med Trop. 2014;47(4):409–413.25229278
   PubMed Web of Science ®Google Scholar
• Schilder AG, Chonmaitree T, Cripps AW, et al. Otitis media. Nat Rev Dis Primers. 2016;2:16063.27604644
   PubMed Web of Science ®Google Scholar
• Kaur CP, Vadivelu J, Chandramathi S. Impact of Klebsiella pneumoniae in lower gastrointestinal tract diseases. J Dig Dis. 2018;19(5):262–271.29573336
   PubMed Web of Science ®Google Scholar
• Nii-Trebi NI. Emerging and neglected infectious diseases: insights, advances, and challenges. Biomed Res Int. 2017;2017(6):1–15. doi:10.1155/2017/5245021
   Google Scholar
• Rello J, Parisella FR, Perez A. Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Rev Clin Pharmacol. 2019;12(7):635–642. doi:10.1080/17512433.2019.161945431092053
   PubMed Web of Science ®Google Scholar
• Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–1184. doi:10.1086/60563019739972
   PubMed Web of Science ®Google Scholar
• Bentley R. The development of penicillin: genesis of a famous antibiotic. Perspect Biol Med. 2005;48(3):444–452. doi:10.1353/pbm.2005.006816089021
   PubMedGoogle Scholar
• Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):382–395. doi:10.1093/jac/dku37925266070
   PubMed Web of Science ®Google Scholar
• Cars O, Hedin A, Heddini A. The global need for effective antibiotics-moving towards concerted action. Drug Resist Updat. 2011;14(2):68–69. doi:10.1016/j.drup.2011.02.00621444235
   PubMed Web of Science ®Google Scholar
• Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658. doi:10.2147/IDR.S17386730349322
   PubMed Web of Science ®Google Scholar
• Ruddaraju LK, Pammi SVN, Guntuku GS, Padavala VS, Kolapalli VRM. A review on anti-bacterials to combat resistance: from ancient era of plants and metals to present and future perspectives of green nano technological combinations. Asian J Pharm Sci. 2020;15(1):42–59. doi:10.1016/j.ajps.2019.03.00232175017
   PubMed Web of Science ®Google Scholar
• Omolo CA, Kalhapure RS, Agrawal N, Rambharose S, Mocktar C, Govender T. Formulation and molecular dynamics simulations of a fusidic acid nanosuspension for simultaneously enhancing solubility and antibacterial activity. Mol Pharm. 2018;15(8):3512–3526. doi:10.1021/acs.molpharmaceut.8b0050529953816
   PubMed Web of Science ®Google Scholar
• Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–283.25859123
   PubMedGoogle Scholar
• McMullan BJ, Andresen D, Blyth CC, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(8):e139–152. doi:10.1016/S1473-3099(16)30024-X27321363
   PubMed Web of Science ®Google Scholar
• Esposito S, Rosazza C, Sciarrabba CS, Principi N. Inhaled antibiotic therapy for the treatment of upper respiratory tract infections. J Aerosol Med Pulm Drug Deliv. 2017;30(1):14–19. doi:10.1089/jamp.2016.130027336220
   PubMed Web of Science ®Google Scholar
• Williamson DA, Carter GP, Howden BP. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev. 2017;30(3):827–860.28592405
   PubMedGoogle Scholar
• MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis. 1997;24(3):457–467. doi:10.1093/clinids/24.3.4579114201
   PubMed Web of Science ®Google Scholar
• Moss DM, Curley P, Kinvig H, Hoskins C, Owen A. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Rev Gastroenterol Hepatol. 2018;12(3):223–236. doi:10.1080/17474124.2018.139979429088978
   PubMed Web of Science ®Google Scholar
• Babadi D, Dadashzadeh S, Osouli M, Daryabari MS, Haeri A. Nanoformulation strategies for improving intestinal permeability of drugs: A more precise look at permeability assessment methods and pharmacokinetic properties changes. J Control Release. 2020;321:669–709. doi:10.1016/j.jconrel.2020.02.04132112856
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277–289. doi:10.1038/s41573-019-0053-031848464
   PubMed Web of Science ®Google Scholar
• Olivera ME, Manzo RH, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci. 2011;100(1):22–33. doi:10.1002/jps.2225920602455
   PubMed Web of Science ®Google Scholar
• Long H, Li X, Sang Z, et al. Improving the pharmacokinetics and tissue distribution of pyrinezolid by self-assembled polymeric micelles. Colloids Surf B Biointerfaces. 2017;156:149–156. doi:10.1016/j.colsurfb.2017.05.01428527358
   PubMed Web of Science ®Google Scholar
• Khan F, Katara R, Ramteke S. Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles. AAPS PharmSciTech. 2010;11(3):1368–1375. doi:10.1208/s12249-010-9505-x20821175
   PubMed Web of Science ®Google Scholar
• Rani S, Gothwal A, Pandey PK, et al. HPMA-PLGA based nanoparticles for effective in vitro delivery of rifampicin. Pharm Res. 2019;36(1):19. doi:10.1007/s11095-018-2543-x
   Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–782. doi:10.1038/nrd261418758474
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.30231877
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing — oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631–644. doi:10.1016/j.addr.2007.05.00317601629
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ghosh S, Sil PC. Role of nanostructures in improvising oral medicine. Toxicol Rep. 2019;6:358–368. doi:10.1016/j.toxrep.2019.04.00431080743
   PubMed Web of Science ®Google Scholar
• BS P, BP V. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharm Sin B. 2017;7(3):260–280. doi:10.1016/j.apsb.2016.09.00528540164
   PubMed Web of Science ®Google Scholar
• Mabilat C, Gros MF, Nicolau D, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis. 2020;39(5):791–797. doi:10.1007/s10096-019-03769-831828686
   PubMed Web of Science ®Google Scholar
• Cowling T, Farrah K. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
   Google Scholar
• Li C, Zhou K, Chen D, et al. <p>Solid lipid nanoparticles with enteric coating for improving stability, palatability, and oral bioavailability of enrofloxacin. Int J Nanomedicine. 2019;14:1619–1631. doi:10.2147/IJN.S18347930880969
   PubMed Web of Science ®Google Scholar
• Murgia X, Loretz B, Hartwig O, Hittinger M, Lehr C-M. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv Drug Deliv Rev. 2018;124:82–97. doi:10.1016/j.addr.2017.10.00929106910
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH. Effect of azithromycin on venetoclax pharmacokinetics in healthy volunteers: implications for dosing venetoclax with p-gp inhibitors. Adv Ther. 2018;35(11):2015–2023. doi:10.1007/s12325-018-0793-y30264382
   PubMed Web of Science ®Google Scholar
• Zupancic O, Partenhauser A, Lam HT, Rohrer J, Bernkop-Schnurch A. Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin. Eur J Pharm Sci. 2016;81:129–136. doi:10.1016/j.ejps.2015.10.00526485536
   PubMed Web of Science ®Google Scholar
• Thummel K. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev. 1997;27(2–3):99–127. doi:10.1016/S0169-409X(97)00039-210837554
   PubMed Web of Science ®Google Scholar
• Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, Lobenberg R. Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class iii drug. J Pharm Pharm Sci. 2017;20:305–318. doi:10.18433/J3CK8828885915
   PubMed Web of Science ®Google Scholar
• Ozturk AA, Yenilmez E, Ozarda MG. Clarithromycin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles for oral administration: effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects. Polymers. 2019;11(10):1632. doi:10.3390/polym11101632
   PubMed Web of Science ®Google Scholar
• Zhao R, Du S, Liu Y, et al. Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy. Theranostics. 2020;10(8):3594–3611. doi:10.7150/thno.4031832206110
   PubMed Web of Science ®Google Scholar
• Maisel K, Reddy M, Xu Q, et al. Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo. Nanomedicine. 2016;11(11):1337–1343. doi:10.2217/nnm-2016-004727171816
   PubMed Web of Science ®Google Scholar
• Umeyor C, Attama A, Uronnachi E, et al. Formulation design and in vitro physicochemical characterization of surface modified self-nanoemulsifying formulations (SNEFs) of gentamicin. Int J Pharm. 2016;497(1–2):161–198. doi:10.1016/j.ijpharm.2015.10.03326657350
   PubMedGoogle Scholar
• Huang W, Zhang C. Tuning the size of poly(lactic-co-glycolic acid) (PLGA) nanoparticles fabricated by nanoprecipitation. Biotechnol J. 2018;13(1):8. doi:10.1002/biot.201700203
   Web of Science ®Google Scholar
• Gurjar R, Chan CYS, Curley P, et al. Inhibitory effects of commonly used excipients on p-glycoprotein in vitro. Mol Pharm. 2018;15(11):4835–4842. doi:10.1021/acs.molpharmaceut.8b0048230350641
   PubMedGoogle Scholar
• Jiang T, Zhang C, Sun W, et al. Doxorubicin encapsulated in TPGS-modified 2d-nanodisks overcomes multidrug resistance. Chemistry. 2020;26(11):2470–2477. doi:10.1002/chem.20190509731912555
   PubMed Web of Science ®Google Scholar
• Tuguntaev RG, Chen S, Eltahan AS, et al. P-gp inhibition and mitochondrial impairment by dual-functional nanostructure based on vitamin e derivatives to overcome multidrug resistance. ACS Appl Mater Interfaces. 2017;9(20):16900–16912. doi:10.1021/acsami.7b0387728463476
   PubMed Web of Science ®Google Scholar
• Bajaj A, Rao MRP, Khole I, Munjapara G. Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate. Drug Dev Ind Pharm. 2013;39(5):635–645. doi:10.3109/03639045.2012.68344022564007
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66(17):2873–2896.19499185
   PubMed Web of Science ®Google Scholar
• Anderson KE, Eliot LA, Stevenson BR, Rogers JA. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm Res. 2001;18(3):316–322. doi:10.1023/A:101100291360111442271
   PubMed Web of Science ®Google Scholar
• Araújo F, Pereira C, Costa J, Barrias C, Granja PL, Sarmento B. In vitro M-like cells genesis through a tissue-engineered triple-culture intestinal model. J Biomed Mater Res B Appl Biomater. 2016;104(4):782–788.26313639
   PubMed Web of Science ®Google Scholar
• Vieira AC, Chaves LL, Pinheiro M, Ferreira D, Sarmento B, Reis S. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. Int J Nanomedicine. 2016;11:2601–2617.27354792
   PubMed Web of Science ®Google Scholar
• Des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1–27.17050027
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001;50(Suppl 1):S127–147.11576699
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJ, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269–282.9050793
   PubMed Web of Science ®Google Scholar
• Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000;89(8):967–978.10906720
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76.21174180
   PubMed Web of Science ®Google Scholar
• Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release. 2018;270:203–225.29199062
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–182.15082340
   PubMed Web of Science ®Google Scholar
• Kollipara S, Gandhi RK. Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations. Acta Pharm Sin B. 2014;4(5):333–349.26579403
   PubMed Web of Science ®Google Scholar
• Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine. 2010;5(10):1595–1616.21143036
   PubMed Web of Science ®Google Scholar
• Wang L, Dong J, Chen J, Eastoe J, Li X. Design and optimization of a new self-nanoemulsifying drug delivery system. J Colloid Interface Sci. 2009;330(2):443–448.19038395
   PubMed Web of Science ®Google Scholar
• Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561–1572.8592652
   PubMed Web of Science ®Google Scholar
• AboulFotouh K, Allam AA, El-Badry M, El-Sayed AM. Self-emulsifying drug-delivery systems modulate P-glycoprotein activity: role of excipients and formulation aspects. Nanomedicine. 2018;13(14):1813–1834.30074420
   PubMed Web of Science ®Google Scholar
• Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res. 2013;30(12):3029–3044.23686373
   PubMed Web of Science ®Google Scholar
• Almeida SRD, Tippavajhala VK. A rundown through various methods used in the formulation of solid self-emulsifying drug delivery systems (S-SEDDS). AAPS PharmSciTech. 2019;20(8):323.31654184
   PubMed Web of Science ®Google Scholar
• Hussain A, Kumar Singh S. et al. Experimental design-based optimization of lipid nanocarrier as delivery system against Mycobacterium species: in vitro and in vivo evaluation. Pharm Dev Technol. 2017;22(7):910–927.27484389
   PubMed Web of Science ®Google Scholar
• Hussain A, Shakeel F, Singh SK, et al. Solidified SNEDDS for the oral delivery of rifampicin: evaluation, proof of concept, in vivo kinetics, and in silico GastroPlus(TM) simulation. Int J Pharm. 2019;566:203–217.31132448
   PubMed Web of Science ®Google Scholar
• He H, Lu Y, Qi J, Zhao W, Dong X, Wu W. Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin. Acta Pharm Sin B. 2018;8(1):97–105.29872626
   PubMed Web of Science ®Google Scholar
• Santo IE, Campardelli R, Albuquerque EC. Liposomes size engineering by combination of ethanol injection and supercritical processing. J Pharm Sci. 2015;104(11):3842–3850.26211426
   PubMed Web of Science ®Google Scholar
• Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11(8):1183–1201.24857605
   PubMed Web of Science ®Google Scholar
• Nguyen TX, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine. 2016;11(9):1169–1185.27074098
   PubMed Web of Science ®Google Scholar
• Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016;23(9):3319–3329.27145899
   PubMed Web of Science ®Google Scholar
• Daeihamed M, Dadashzadeh S, Haeri A, Akhlaghi MF. Potential of Liposomes for Enhancement of Oral Drug Absorption. Curr Drug Deliv. 2017;14(2):289–303.26768542
   PubMed Web of Science ®Google Scholar
• Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441(1–2):693–700.23089580
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557–570.22212900
   PubMed Web of Science ®Google Scholar
• Arregui JR, Kovvasu SP, Betageri GV. Daptomycin proliposomes for oral delivery: formulation, characterization, and in vivo pharmacokinetics. AAPS PharmSciTech. 2018;19(4):1802–1809.29616488
   PubMed Web of Science ®Google Scholar
• Senior K. Bilosomes: the answer to oral vaccine delivery? Drug Discov Today. 2001;6(20):1031–1032.11590024
   PubMed Web of Science ®Google Scholar
• Lopes-de-Campos D, Pinto RM, Lima SAC, et al. Delivering amoxicillin at the infection site - a rational design through lipid nanoparticles. Int J Nanomedicine. 2019;14:2781–2795.31114195
   PubMed Web of Science ®Google Scholar
• Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems–an overview. Adv Colloid Interface Sci. 2012;183–184:46–54.
   PubMed Web of Science ®Google Scholar
• Zhong M, Feng Y, Liao H, et al. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. Pharm Res. 2014;31(10):2857–2867.25208873
   PubMed Web of Science ®Google Scholar
• Imran M, Shah MR, Ullah F, et al. Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin. Drug Deliv. 2016;23(9):3653–3664.27886514
   PubMed Web of Science ®Google Scholar
• Imran M, Shah MR, Ullah F, et al. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime. Int J Pharm. 2016;505(1–2):122–132.27050867
   PubMedGoogle Scholar
• Ullah S, Shah MR, Shoaib M, et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. Drug Deliv. 2016;23(9):3480–3491.27247018
   PubMed Web of Science ®Google Scholar
• Imran M, Shah MR, Ullah F, et al. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime. Artif Cells Nanomed Biotechnol. 2017;45(7):1440–1451.27822958
   PubMed Web of Science ®Google Scholar
• Ullah S, Shah MR, Shoaib M, et al. Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability. Artif Cells Nanomed Biotechnol. 2018;46(3):568–578.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.10840199
   PubMed Web of Science ®Google Scholar
• Pandya NT, Jani P, Vanza J, Tandel H. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension. Colloids Surf B Biointerfaces. 2018;165:37–44.29453084
   PubMed Web of Science ®Google Scholar
• Chokshi NV, Khatri HN, Patel MM. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis. Drug Dev Ind Pharm. 2018;44(12):1975–1989.30058392
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50(1–2):61–80.11489334
   PubMed Web of Science ®Google Scholar
• Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol Pharm. 2012;9(9):2542–2553.22845020
   PubMed Web of Science ®Google Scholar
• Sharma M, Gupta N, Gupta S. Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety. RSC Adv. 2016;6(80):76621–76631.
   Web of Science ®Google Scholar
• Ozturk AA, Aygul A, Senel B. Influence of glyceryl behenate, tripalmitin and stearic acid on the properties of clarithromycin incorporated solid lipid nanoparticles (SLNs): formulation, characterization, antibacterial activity and cytotoxicity. J Drug Deliv Sci Technol. 2019;54:16.
   Web of Science ®Google Scholar
• Nirbhavane P, Vemuri N, Kumar N, Khuller GK. Lipid nanocarrier-mediated drug delivery system to enhance the oral bioavailability of rifabutin. AAPS PharmSciTech. 2017;18(3):829–837.27350276
   PubMed Web of Science ®Google Scholar
• Kalhapure RS, Mocktar C, Sikwal DR, et al. Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2014;117:303–311.24667076
   PubMed Web of Science ®Google Scholar
• Zheng CJ, Yoo JS, Lee TG, Cho HY, Kim YH, Kim WG. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett. 2005;579(23):5157–5162. doi:10.1016/j.febslet.2005.08.02816146629
   PubMed Web of Science ®Google Scholar
• Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol. 2010;85(6):1629–1642. doi:10.1007/s00253-009-2355-319956944
   PubMed Web of Science ®Google Scholar
• Smith PA, Romesberg FE. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat Chem Biol. 2007;3(9):549–556. doi:10.1038/nchembio.2007.2717710101
   PubMed Web of Science ®Google Scholar
• Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7(1):41–55. doi:10.2174/18722101380448482722946628
   PubMed Web of Science ®Google Scholar
• Banerjee S, Roy S, Nath Bhaumik K, Kshetrapal P, Pillai J. Comparative study of oral lipid nanoparticle formulations (LNFs) for chemical stabilization of antitubercular drugs: physicochemical and cellular evaluation. Artif Cells Nanomed Biotechnol. 2018;46(sup1):540–558. doi:10.1080/21691401.2018.143164829373927
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73(2–3):137–172. doi:10.1016/S0168-3659(01)00299-111516494
   PubMed Web of Science ®Google Scholar
• Gong J, Chen M, Zheng Y, Wang S, Wang Y. Polymeric micelles drug delivery system in oncology. J Control Release. 2012;159(3):312–323. doi:10.1016/j.jconrel.2011.12.01222285551
   PubMed Web of Science ®Google Scholar
• Xiong XB, Falamarzian A, Garg SM, Lavasanifar A. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. J Control Release. 2011;155(2):248–261. doi:10.1016/j.jconrel.2011.04.02821621570
   PubMed Web of Science ®Google Scholar
• Judy E, Pagariya D, Kishore N. Drug Partitioning in Micellar Media and Its Implications in Rational Drug Design: insights with Streptomycin. Langmuir. 2018;34(11):3467–3484. doi:10.1021/acs.langmuir.7b0434629482319
   PubMed Web of Science ®Google Scholar
• Chu B, Qu Y, Huang Y, et al. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. Int J Pharm. 2016;500(1–2):345–359. doi:10.1016/j.ijpharm.2016.01.03026794876
   PubMedGoogle Scholar
• Li W, Li X, Gao Y, et al. Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity. Mol Pharm. 2014;11(1):71–80. doi:10.1021/mp400422324256068
   PubMedGoogle Scholar
• Lu A, Petit E, Jelonek K, et al. Self-assembled micelles prepared from bio-based hydroxypropyl methyl cellulose and polylactide amphiphilic block copolymers for anti-tumor drug release. Int J Biol Macromol. 2020;154:39–47. doi:10.1016/j.ijbiomac.2020.03.09432173435
   PubMed Web of Science ®Google Scholar
• Sun C, Li W, Ma P, et al. Development of TPGS/F127/F68 mixed polymeric micelles: enhanced oral bioavailability and hepatoprotection of syringic acid against carbon tetrachloride-induced hepatotoxicity. Food Chem Toxicol. 2020;137:111126. doi:10.1016/j.fct.2020.11112631954714
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhang X, Peng S, Julian McClements D. Impact of curcumin delivery system format on bioaccessibility: nanocrystals, nanoemulsion droplets, and natural oil bodies. Food Funct. 2019;10(7):4339–4349. doi:10.1039/C8FO02510J31276144
   PubMed Web of Science ®Google Scholar
• Sharif Makhmal Zadeh B, Esfahani G, Salimi A. Permeability of ciprofloxacin-loaded polymeric micelles including ginsenoside as p-glycoprotein inhibitor through a caco-2 cells monolayer as an intestinal absorption model. Molecules. 2018;23(8):1904. doi:10.3390/molecules23081904
   PubMed Web of Science ®Google Scholar
• Arafat M, Kirchhoefer C, Mikov M. Mixed micelles loaded with bile salt: an approach to enhance intestinal transport of the BCS class iii drug cefotaxime in rats. Eur J Drug Metab Pharmacokinet. 2017;42(4):635–645. doi:10.1007/s13318-016-0375-927686853
   PubMed Web of Science ®Google Scholar
• Najafi M, Kordalivand N, Moradi MA, et al. Native chemical ligation for cross-linking of flower-like micelles. Biomacromolecules. 2018;19(9):3766–3775. doi:10.1021/acs.biomac.8b0090830102855
   PubMed Web of Science ®Google Scholar
• Higashi N, Matsubara S, Nishimura SN, Koga T. Stepwise thermo-responsive amino acid-derived triblock vinyl polymers: ATRP synthesis of polymers, aggregation, and gelation properties via flower-like micelle formation. Materials. 2018;11(3):424.
   PubMed Web of Science ®Google Scholar
• Moretton MA, Hocht C, Taira C, Sosnik A. Rifampicin-loaded ‘flower-like’ polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid. Nanomedicine. 2014;9(11):1635–1650. doi:10.2217/nnm.13.15424410279
   PubMed Web of Science ®Google Scholar
• George A, Shah PA, Shrivastav PS. Natural biodegradable polymers based nano-formulations for drug delivery: A review. Int J Pharm. 2019;561:244–264. doi:10.1016/j.ijpharm.2019.03.01130851391
   PubMed Web of Science ®Google Scholar
• Rauta PR, Das NM, Nayak D, Ashe S, Nayak B. Enhanced efficacy of clindamycin hydrochloride encapsulated in PLA/PLGA based nanoparticle system for oral delivery. IET Nanobiotechnol. 2016;10(4):254–261. doi:10.1049/iet-nbt.2015.002127463797
   PubMed Web of Science ®Google Scholar
• Taipaleenmäki E, Städler B. Recent advancements in using polymers for intestinal mucoadhesion and mucopenetration. Macromol Biosci. 2020;20(3):e1900342. doi:10.1002/mabi.20190034232045102
   PubMed Web of Science ®Google Scholar
• Bachhav SS, Dighe VD, Devarajan PV. Exploring Peyer’s patch uptake as a strategy for targeted lung delivery of polymeric rifampicin nanoparticles. Mol Pharm. 2018;15(10):4434–4445. doi:10.1021/acs.molpharmaceut.8b0038230106591
   PubMedGoogle Scholar
• Lang X, Wang T, Sun M, Chen X, Liu Y. Advances and applications of chitosan-based nanomaterials as oral delivery carriers: A review. Int J Biol Macromol. 2020;154:433–445. doi:10.1016/j.ijbiomac.2020.03.14832194103
   PubMed Web of Science ®Google Scholar
• Huang TW, Ho YC, Tsai TN, Tseng CL, Lin C, Mi FL. Enhancement of the permeability and activities of epigallocatechin gallate by quaternary ammonium chitosan/fucoidan nanoparticles. Carbohydr Polym. 2020;242:116312. doi:10.1016/j.carbpol.2020.11631232564860
   PubMed Web of Science ®Google Scholar
• Wang J, Kong M, Zhou Z, et al. Mechanism of surface charge triggered intestinal epithelial tight junction opening upon chitosan nanoparticles for insulin oral delivery. Carbohydr Polym. 2017;157:596–602. doi:10.1016/j.carbpol.2016.10.02127987967
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Patel HM, Surana SJ, Vanjari YH, Belgamwar VS, Pardeshi CV. N,N,N-Trimethyl chitosan: an advanced polymer with myriad of opportunities in nanomedicine. Carbohydr Polym. 2017;157:875–902. doi:10.1016/j.carbpol.2016.10.04127988003
   PubMed Web of Science ®Google Scholar
• Teng Z, Luo Y, Wang Q. Carboxymethyl chitosan-soy protein complex nanoparticles for the encapsulation and controlled release of vitamin D(3). Food Chem. 2013;141(1):524–532. doi:10.1016/j.foodchem.2013.03.04323768389
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A, Guggi D, Pinter Y. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release. 2004;94(1):177–186. doi:10.1016/j.jconrel.2003.10.00514684281
   PubMed Web of Science ®Google Scholar
• Cole H, Bryan D, Lancaster L, Mawas F, Vllasaliu D. Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery. Carbohydr Polym. 2018;190:248–254. doi:10.1016/j.carbpol.2018.02.08429628245
   PubMed Web of Science ®Google Scholar
• Palazzo C, Trapani G, Ponchel G, Trapani A, Vauthier C. Mucoadhesive properties of low molecular weight chitosan- or glycol chitosan- and corresponding thiomer-coated poly(isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm. 2017;117:315–323. doi:10.1016/j.ejpb.2017.04.02028455206
   PubMed Web of Science ®Google Scholar
• Akhtar B, Muhammad F, Aslam B, Saleemi MK, Sharif A. Pharmacokinetic profile of chitosan modified poly lactic co-glycolic acid biodegradable nanoparticles following oral delivery of gentamicin in rabbits. Int J Biol Macromol. 2020;164:1493–1500. doi:10.1016/j.ijbiomac.2020.07.20632735923
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483–507. doi:10.2147/DDDT.S99651
   PubMed Web of Science ®Google Scholar
• Varlamov VP, Il’ina AV, Shagdarova BT, Lunkov AP, Mysyakina IS. Chitin/Chitosan and Its Derivatives: fundamental Problems and Practical Approaches. Biochemistry (Mosc). 2020;85(Suppl 1):S154–S176. doi:10.1134/S000629792014008432087058
   PubMed Web of Science ®Google Scholar
• Chaves LL, Costa Lima SA, Vieira ACC, et al. Development of PLGA nanoparticles loaded with clofazimine for oral delivery: assessment of formulation variables and intestinal permeability. Eur J Pharm Sci. 2018;112:28–37. doi:10.1016/j.ejps.2017.11.00429122712
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy. I: preparation and characterization of tetracyline-loaded chitosan microspheres. Int J Pharm. 2002;235(1–2):87–94. doi:10.1016/S0378-5173(01)00985-111879743
   PubMed Web of Science ®Google Scholar
• Chang CH, Lin YH, Yeh CL, et al. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori. Biomacromolecules. 2010;11(1):133–142. doi:10.1021/bm900985h19924885
   PubMed Web of Science ®Google Scholar
• Arif M, Dong QJ, Raja MA, Zeenat S, Chi Z, Liu CG. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Mater Sci Eng C Mater Biol Appl. 2018;83:17–24. doi:10.1016/j.msec.2017.08.03829208276
   PubMed Web of Science ®Google Scholar
• Jing ZW, Jia YY, Wan N, et al. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori. Biomaterials. 2016;84:276–285. doi:10.1016/j.biomaterials.2016.01.04526851392
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827–840. doi:10.1211/002235702369115233860
   PubMed Web of Science ®Google Scholar
• Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2(2):81–87. doi:10.4103/2231-4040.8295022171298
   PubMedGoogle Scholar
• Fülöp V, Jakab G, Bozó T, et al. Study on the dissolution improvement of albendazole using reconstitutable dry nanosuspension formulation. Eur J Pharm Sci. 2018;123:70–78. doi:10.1016/j.ejps.2018.07.02730010031
   PubMed Web of Science ®Google Scholar
• Medarevic D, Djuris J, Ibric S, Mitric M, Kachrimanis K. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. Int J Pharm. 2018;540(1–2):150–161. doi:10.1016/j.ijpharm.2018.02.01129438724
   PubMed Web of Science ®Google Scholar
• Sawant KK, Patel MH, Patel K. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. Drug Dev Ind Pharm. 2016;42(5):758–768. doi:10.3109/03639045.2015.110434426548349
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Patra M, Dutta D, Banik M, Basu T. Tetracycline-loaded calcium phosphate nanoparticle (Tet-CPNP): rejuvenation of an obsolete antibiotic to further action. Biochim Biophys Acta. 2016;1860(9):1929–1941. doi:10.1016/j.bbagen.2016.06.00627288585
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Dutta D, Patra M, Chatterjee B, Basu T. Nanonized tetracycline cures deadly diarrheal disease ‘shigellosis’ in mice, caused by multidrug-resistant Shigella flexneri 2a bacterial infection. Nanomedicine. 2019;18:402–413. doi:10.1016/j.nano.2018.11.00430448527
   PubMed Web of Science ®Google Scholar
• Rode A, Sharma S, Mishra DK. Carbon nanotubes: classification, method of preparation and pharmaceutical application. Curr Drug Deliv. 2018;15(5):620–629. doi:10.2174/156720181566617122112471129268686
   PubMed Web of Science ®Google Scholar
• Wong BS, Yoong SL, Jagusiak A, et al. Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev. 2013;65(15):1964–2015. doi:10.1016/j.addr.2013.08.00523954402
   PubMed Web of Science ®Google Scholar
• Karimi M, Solati N, Ghasemi A, et al. Carbon nanotubes part II: a remarkable carrier for drug and gene delivery. Expert Opin Drug Deliv. 2015;12(7):1089–1105. doi:10.1517/17425247.2015.100430925613837
   PubMed Web of Science ®Google Scholar
• Zhang LP, Tan XX, Huang YP, Liu ZS. Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. Eur J Pharm Biopharm. 2018;127:150–158. doi:10.1016/j.ejpb.2018.02.01229438726
   PubMed Web of Science ®Google Scholar
• Zhang LP, Wang XL, Pang QQ, et al. Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. Int J Pharm. 2017;532(1):365–373. doi:10.1016/j.ijpharm.2017.09.00828888975
   PubMed Web of Science ®Google Scholar
• Vadia N, Rajput S. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement. Eur J Pharm Sci. 2012;45(1–2):8–18. doi:10.1016/j.ejps.2011.10.01622067974
   PubMed Web of Science ®Google Scholar
• Doadrio AL, Sánchez-Montero JM, Doadrio JC, Salinas AJ, Vallet-Regí M. Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill. Eur J Pharm Sci. 2017;97:1–8. doi:10.1016/j.ejps.2016.11.00227818251
   PubMed Web of Science ®Google Scholar
• Florek J, Caillard R, Kleitz F. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers. Nanoscale. 2017;9(40):15252–15277. doi:10.1039/C7NR05762H28984885
   PubMed Web of Science ®Google Scholar
• Tan X, Liu X, Zhang Y, et al. Silica nanoparticles on the oral delivery of insulin. Expert Opin Drug Deliv. 2018;15(8):805–820. doi:10.1080/17425247.2018.150325030025216
   PubMed Web of Science ®Google Scholar
• Mudakavi RJ, Raichur AM, Chakravortty D. Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections. RSC Adv. 2014;4(105):61160–61166. doi:10.1039/C4RA12973C
   Web of Science ®Google Scholar
• Xia X, Pethe K, Kim R, et al. Encapsulation of anti-tuberculosis drugs within mesoporous silica and intracellular antibacterial activities. Nanomaterials. 2014;4(3):813–826. doi:10.3390/nano403081328344250
   PubMed Web of Science ®Google Scholar
• Uhl P, Pantze S, Storck P, et al. Oral delivery of vancomycin by tetraether lipid liposomes. Eur J Pharm Sci. 2017;108:111–118. doi:10.1016/j.ejps.2017.07.01328716758
   PubMed Web of Science ®Google Scholar
• Singh H, Jindal S, Singh M, Sharma G, Kaur IP. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int J Pharm. 2015;485(1–2):138–151. doi:10.1016/j.ijpharm.2015.02.05025769294
   PubMedGoogle Scholar
• Chaves LL, Lima S, Vieira ACC, Ferreira D, Sarmento B, Reis S. Overcoming clofazimine intrinsic toxicity: statistical modelling and characterization of solid lipid nanoparticles. J R Soc Interface. 2018;15:139. doi:10.1098/rsif.2017.0932
   Web of Science ®Google Scholar
• Dong Z, Xie S, Zhu L, Wang Y, Wang X, Zhou W. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. Drug Deliv. 2011;18(6):441–450. doi:10.3109/10717544.2011.57710921554156
   PubMed Web of Science ®Google Scholar
• Xie S, Zhu L, Dong Z, Wang Y, Wang X, Zhou W. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomedicine. 2011;6:547–555.21468357
   PubMed Web of Science ®Google Scholar
• Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441(1–2):202–212. doi:10.1016/j.ijpharm.2012.11.04223220081
   PubMed Web of Science ®Google Scholar
• Patel MD, Date PV, Gaikwad RV, Samad A, Malshe VC, Devarajan PV. Comparative evaluation of polymeric nanoparticles of rifampicin comprising Gantrez and poly(ethylene sebacate) on pharmacokinetics, biodistribution and lung uptake following oral administration. J Biomed Nanotechnol. 2014;10(4):687–694. doi:10.1166/jbn.2014.173924734521
   PubMed Web of Science ®Google Scholar
• Rani S, Rana R, Saraogi GK, Kumar V, Gupta U. Self-emulsifying oral lipid drug delivery systems: advances and challenges. AAPS Pharm Sci Tech. 2019;20(3):129. doi:10.1208/s12249-019-1335-x
   PubMed Web of Science ®Google Scholar
• He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta Pharm Sin B. 2019;9(1):36–48. doi:10.1016/j.apsb.2018.06.00530766776
   PubMed Web of Science ®Google Scholar
• Raza A, Sime FB, Cabot PJ, Maqbool F, Roberts JA, Falconer JR. Solid nanoparticles for oral antimicrobial drug delivery: a review. Drug Discov Today. 2019;24(3):858–866. doi:10.1016/j.drudis.2019.01.00430654055
   PubMed Web of Science ®Google Scholar
• Simoes SM, Figueiras AR, Veiga F, Concheiro A, Alvarez-Lorenzo C. Polymeric micelles for oral drug administration enabling locoregional and systemic treatments. Expert Opin Drug Deliv. 2015;12(2):297–318. doi:10.1517/17425247.2015.96084125227130
   PubMed Web of Science ®Google Scholar
• Chen D, Ding PT, Deng YH, Wang SL. [Advances in the study of polymeric micelles used in oral administration]. Yao Xue Xue Bao. 2010;45(5):560–564. Chinese.20931755
   PubMedGoogle Scholar
• Singh SK, Vaidya Y, Gulati M, Bhattacharya S, Garg V, Pandey NK. Nanosuspension: principles, perspectives and practices. Curr Drug Deliv. 2016;13(8):1222–1246. doi:10.2174/156720181366616010112045226721266
   PubMed Web of Science ®Google Scholar
• Chen A, Shi Y, Yan Z, et al. Dosage form developments of nanosuspension drug delivery system for oral administration route. Curr Pharm Des. 2015;21(29):4355–4365.26323418
   PubMed Web of Science ®Google Scholar
• Bharti C, Gulati N, Nagaich U. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig. 2015;5(3):124–133. doi:10.4103/2230-973X.160844
   PubMed Web of Science ®Google Scholar